Macular edema is swelling in the macula, the small central area of the retina responsible for sharp, detailed vision. Fluid leaks from damaged blood vessels and accumulates in retinal tissue, distorting or blurring the center of your visual field. It’s one of the most common causes of vision loss in people with diabetes, affecting roughly 25% of all people with the disease at some point, but it can also develop after eye surgery, retinal vein blockages, and other conditions.
How Fluid Builds Up in the Retina
Your retina normally stays dry. A system of tightly sealed blood vessels, known as the blood-retinal barrier, prevents proteins and fluid from leaking into the surrounding tissue. The macula in particular relies on this dryness for clear light transmission to its dense concentration of photoreceptor cells.
When disease or injury damages these blood vessels, their walls become permeable. Proteins and other molecules that normally stay inside the bloodstream seep into the retina, pulling water with them. At the same time, the retina’s natural drainage mechanisms can’t keep pace with the incoming fluid. The result is swelling, often in a pattern of tiny fluid-filled pockets called cysts, concentrated right where your most precise vision originates. The macula is especially vulnerable because of its high metabolic demand, limited drainage capacity, and the arrangement of its nerve fibers, which can trap fluid once it arrives.
Common Causes
Diabetes is the leading cause. Chronically elevated blood sugar damages the tiny blood vessels in the retina, thickening their walls and killing the support cells (pericytes) that help maintain vessel integrity. Over time, the vessels become leaky, and plasma components seep into the surrounding retina. This process can happen at any stage of diabetic eye disease, not just in advanced cases.
Retinal vein occlusion, a blockage in one of the veins draining blood from the retina, is the second most common cause. The blockage raises pressure inside the capillaries around the macula and disrupts blood flow, forcing fluid out through damaged vessel walls.
Cataract surgery also carries a risk. Clinically significant swelling that affects vision occurs in about 1 to 2% of patients, typically peaking around six weeks after the procedure. Subclinical swelling, detectable on imaging but not necessarily noticeable to the patient, shows up in as many as 30 to 40% of eyes after surgery. This post-surgical form is sometimes called Irvine-Gass syndrome and usually resolves on its own or with anti-inflammatory drops.
Other causes include uveitis (inflammation inside the eye), age-related macular degeneration, radiation treatment near the eye, and certain medications.
What It Looks and Feels Like
Macular edema doesn’t cause pain. The most common early symptom is blurry or hazy central vision, as though you’re looking through a smudged window. Colors may appear washed out or faded, especially in the center of your visual field.
Some people experience metamorphopsia, a visual distortion that makes straight lines appear wavy or bent. Objects may look larger, smaller, or misshapen. These distortions are most noticeable when looking at grids, text, or doorframes. In mild cases, only one eye is affected, and the other eye compensates enough that you might not notice the problem right away. That delay is one reason regular eye exams matter for people at higher risk.
How It’s Diagnosed
An eye doctor can sometimes spot macular swelling during a dilated eye exam, but the standard diagnostic tool is optical coherence tomography (OCT). This painless imaging scan creates a cross-sectional picture of the retina and measures its thickness in microns. A normal central retinal thickness is around 200 microns. Values above 300 microns generally indicate significant edema, though the threshold for treatment depends on the cause and how much vision has been affected.
A fluorescein angiography test, where dye is injected into a vein in the arm and photographed as it travels through the retinal blood vessels, can reveal exactly where leakage is occurring. Together, these two tests give a detailed map of the swelling and its source.
Treatment Options
The primary treatment for most forms of macular edema is a series of injections directly into the eye. These injections deliver medications that block a protein called VEGF, which drives both blood vessel leakage and the growth of abnormal new vessels. The procedure sounds alarming, but the eye is numbed with drops beforehand and the injection itself takes only a few seconds.
The most commonly used anti-VEGF drugs include ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin). Newer formulations, including faricimab (Vabysmo) and a higher-dose version of aflibercept, can extend the interval between injections to 12 or even 16 weeks, reducing the burden of frequent office visits. In earlier treatment regimens, injections were needed every four to six weeks.
Steroid implants are an alternative, particularly for patients who don’t respond well to anti-VEGF therapy or who have inflammation-driven edema. A tiny implant placed inside the eye releases medication gradually over weeks to months. Vision improvement can begin within a week of the procedure, with benefits typically lasting two to three months. The trade-off is that steroid implants can raise pressure inside the eye and accelerate cataract formation, so they require closer monitoring.
For diabetic macular edema specifically, tighter control of blood sugar, blood pressure, and cholesterol can slow the underlying vascular damage and reduce the likelihood of recurrence. Treatment of the swelling itself works best alongside management of the systemic disease.
Vision Recovery and What to Expect
How much vision you recover depends on how long the swelling has been present and what caused it. In clinical studies of steroid implants for vein-occlusion-related edema, about 10% of treated eyes gained three or more lines on a vision chart within the first week, and meaningful improvement lasted an average of 70 days. Anti-VEGF injections tend to show peak benefit after several monthly treatments rather than a single dose.
The critical factor is timing. Fluid that sits in the macula for months can permanently damage photoreceptors and the delicate nerve connections that relay visual information to the brain. Early treatment preserves more of the retina’s structure and gives you the best chance of recovering clear central vision. Chronic or recurrent edema, where the swelling returns each time treatment wears off, carries a higher risk of lasting vision loss even with ongoing therapy.
Most people with macular edema need repeated treatments over months or years rather than a one-time fix. The goal shifts over time from reducing the initial swelling to maintaining stability, gradually extending the interval between injections as the retina responds. Consistent follow-up and OCT monitoring allow your eye doctor to catch recurrences before they cause additional damage.